-
Feb 13, 2024 | 
lexblog.com | Grant Castle |Mosa Mkhize |Roderick Dirkzwager
On 26 January 2024, the European Medicines Agency (EMA) announced that it has received a €10 million grant from the European Commission to support regulatory systems in Africa, and in particular for the setting up of the African Medicines Agency (AMA). Although still in its early stages as an agency, AMA shows significant promise to harmonize the regulatory landscape across the continent in order to improve access to quality, safe and efficacious medical products in Africa.
-
Feb 12, 2024 | 
lexblog.com | Grant Castle |Mosa Mkhize |Roderick Dirkzwager
On 26 January 2024, the European Medicines Agency (EMA) announced that it has received a €10 million grant from the European Commission to support regulatory systems in Africa, and in particular for the setting up of the African Medicines Agency (AMA). Although still in its early stages as an agency, AMA shows significant promise to harmonize the regulatory landscape across the continent in order to improve access to quality, safe and efficacious medical products in Africa.
-
Feb 12, 2024 | 
lexology.com | Grant Castle |Mosa Mkhize |Roderick Dirkzwager
On 26 January 2024, the European Medicines Agency (EMA) announced that it has received a €10 million grant from the European Commission to support regulatory systems in Africa, and in particular for the setting up of the African Medicines Agency (AMA). Although still in its early stages as an agency, AMA shows significant promise to harmonize the regulatory landscape across the continent in order to improve access to quality, safe and efficacious medical products in Africa.
-
Jan 23, 2024 | 
chicagopolicyreview.org | Grant Castle
The views expressed in this article are those solely of the author and do not reflect the policies or views of the U.S. government or the U.S. Agency for International Development. Venezuela’s autocratic government signed an agreement with opposition parties October 17, 2023, laying the groundwork for potentially competitive presidential elections in 2024. In return, the U.S. pledged to lift some of its ‘maximum pressure’ sanctions on Venezuela imposed by the Trump Administration.
-
Oct 9, 2023 | 
chicagopolicyreview.org | Grant Castle
In December 2022, Belgian authorities arrested Eva Kaili, a vice president of the European Parliament, amidst allegations that she accepted bribes from Qatar. This corruption scandal followed similar concerns in the European Union (EU) over the influence of Russian energy lobbyists during debates regarding sanctions against Russia.
-
May 4, 2023 | 
lexology.com | Grant Castle |Kristof Van Quathem
On April 26, 2023, the European Commission proposed the long awaited reform of the EU’s pharmaceutical regulations (see here to view our previous blogs on the subject). This blog post discusses the data protection aspects of the proposals, which relate to the data processing activities of the European Medicines Agency (“EMA”). Legal basis – The proposal grants the EMA a broad right to use health data for its public health tasks, such as the evaluation and monitoring of medical products.
-
May 4, 2023 | 
lexblog.com | Grant Castle |Kristof Van Quathem
On April 26, 2023, the European Commission proposed the long awaited reform of the EU’s pharmaceutical regulations (see here to view our previous blogs on the subject). This blog post discusses the data protection aspects of the proposals, which relate to the data processing activities of the European Medicines Agency (“EMA”). Legal basis – The proposal grants the EMA a broad right to use health data for its public health tasks, such as the evaluation and monitoring of medical products.
-
Apr 28, 2023 | 
lexology.com | Sean Finan |Grant Castle |Bart Van Vooren |Yuliya Gevrenova
“Delays in clinical trials result in delays of potentially life-saving treatments”The European Commission is streamlining the rules for clinical trials of medicines consisting of, or containing genetically modified organisms (“GMOs”). Under the current EU GMO framework, getting authorization for clinical trials of GMO medicines is a long and costly process. Industry groups have vocally criticized it; and the Commission itself has voiced the need for change.
-
Apr 28, 2023 | 
lexology.com | Sean Finan |Grant Castle |Bart Van Vooren |Yuliya Gevrenova
Pharmaceutical companies take note: the EU plans to refuse marketing authorizations for environmentally-unfriendly medicines. The EU has published a package of revisions to the bloc’s common pharmaceutical regime. Many revisions aim to reduce the environmental impact of human medicinal products.
-
Apr 28, 2023 | 
lexblog.com | Sean Finan |Grant Castle |Bart Van Vooren |Yuliya Gevrenova
“Delays in clinical trials result in delays of potentially life-saving treatments”The European Commission is streamlining the rules for clinical trials of medicines consisting of, or containing genetically modified organisms (“GMOs”). Under the current EU GMO framework, getting authorization for clinical trials of GMO medicines is a long and costly process. Industry groups have vocally criticized it; and the Commission itself has voiced the need for change.
